New Delhi, Feb 2 (PTI) Alembic Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic version of fesoterodine fumarate extended-release tablets, used for overactive bladder in adults with symptoms of urinary incontinence, urgency, and frequency.

The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for fesoterodine fumarate extended-release tablets is for strengths of 4 mg and 8 mg, the company said in a statement.

Also Read | Netflix Users Can Now Remove Content From ‘Continue Watching List’.

"The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc," it added.

These tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

Also Read | Moto Edge 30 Pro Leaked Renders Reveal Triple Rear Cameras, Punch-Hole Display & More.

"It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses," Alembic said.

Citing IQVIA data, the company said fesoterodine fumarate extended-release tablets, 4 mg and 8 mg have an estimated market size of USD 225 million for 12-months ending September 2021.

Alembic said it has received 20 approvals (14 final approvals and 6 tentative approvals) year-to-date and a cumulative total of 159 abbreviated new drug application (ANDA) approvals from USFDA.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)